Abstract

This study was designed to compare results obtained from two separate on-site drug testing kits (ONTRAK TESTCUP and Abuscreen ONTRAK) with those obtained from laboratory based immunoassay and GC/MS. Abuscreen ONLINE immunoassay was used to select 250 negative samples and 100 presumptive-positive samples each for cocaine/metabolites, opiates and cannabinoids. Presumptive-positive samples were selected if the immunoassay response was ⩾300 ng/mL for cocaine/metabolites (BZE), ⩾300 ng/mL for opiates or ⩾50 ng/mL for cannabinoids (THC-COOH). GC/MS was used to confirm that each selected sample contained ⩾150 ng/mL BZE, ⩾300 ng/mL morphine/codeine or ⩾15 ng/mL THC-COOH.

TESTCUP results had a 100% agreement with GC/MS and a >99% agreement with ONLINE when testing negative samples. The agreement between TESTCUP and ONLINE results for samples containing opiates was 100%. Results of testing samples containing BZE with TESTCUP demonstrated a 98% agreement with both GC/MS and ONLINE. Both discrepant samples contained BZE at concentrations ⩽300 ng/mL. The least agreement between TESTCUP and ONLINE results was found when testing samples containing THC-COOH. The agreement with ONLINE and GC/MS was 92% and all discrepant samples had GC/MS determined THC-COOH concentrations less than 50 ng/mL. A 100% agreement was obtained between expected and recorded TESTCUP results for QC samples fortified to contained BZE, morphine or THC-COOH at concentrations within 120% of the screening cutoffs.

ONTRAK had a 100% agreement with both GC/MS and ONLINE when testing negative samples and samples that contained opiates. ONTRAK had a 91% agreement with GC/MS and ONLINE for testing of samples that contained BZE. The least agreement between ONTRAK and ONLINE results was found when testing samples that contained THC-COOH. The agreement was 89%, however, all discrepant samples contained GC/MS concentrations of THC-COOH less that the 50 ng/mL cutoff. With ONTRAK, a 100% agreement was obtained between expected and recorded results on QC samples that contained morphine or THC-COOH and a 97.7% agreement was obtained between expected and recorded results on QC samples that contained BZE.

References

1.
Rollins
D E
,
Jennison
T A
,
Jones
G
.
Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs
.
Clin Chem
1990
;
36
:
602
-
6
.
2.
Fitzgerald
R L
,
Rexin
D A
,
Herold
D A
.
Detecting benzodiazepines: immunoassay compared with negative chemical ionization gas chromatography/mass spectrometry
.
Clin Chem
1994
;
40
/
3
:
373
-
80
.
3.
Wu
A HB
,
Wong
S S
,
Johnson
K G
,
Callies
J
,
Shu
D X
,
Dunn
W E
, et al
.
Evaluation of the triage system for emergency drugs-of-abuse testing in urine
.
J Anal Toxicol
1993
;
17
:
241
-
3
.
4.
Koch
T R
,
Raglin
R L
,
Kirk
S
,
Bruni
J F
.
Improved screening for benzodiazepine metabolites in urine using the Triage™ panel for drugs of abuse
.
J Anal Toxicol
1994
;
18
:
168
-
72
.
5.
Baker
D P
,
Guintu
D C
,
Mendoza
D A
,
Calderone
M E
,
Shepp
P F
,
Murphy
M S
,
Green
M
.
ABSTRACT Evaluation of Abuscreen Ontrak™ Assays: Correlation with RIA and GC/MS
.
Presented AAF
,
New Orleans, LA
1991
.
6.
Baker
D P
,
Guintu
D C
,
Mendoza
D A
,
Calderone
M E
,
Shepp
P F
,
Murphy
M S
,
Greene
M
.
Abstract Evaluation of Abuscreen Ontrak™ Assays: Correlation between Clinically Trained Personnel and Non-Clinical Personnel in the Field
.
Presented AAFS
,
New Orleans, LA
1991
.
7.
Armbruster
D A
,
Krolak
J M
.
Screening for Drugs of Abuse with the Roche ONTRAK Assays
.
J Anal Toxicol
1992
;
16
:
172
-
5
.
8.
Ferrara
S D
,
Tedeschi
L
,
Frison
G
,
Brusini
G
,
Castagna
F
,
Bernardelli
B
,
Soregaroli
D
.
Drugs-of-abuse testing in urine: statistical approach and experimental comparison of immunochemical and chromatographic techniques
.
J Anal Toxicol
1994
;
18
:
278
-
91
.
9.
Jenkins
A J
,
Darwin
W D
,
Heustis
M A
,
Cone
E J
,
Mitchell
J M
.
Validity testing of the accuPINCH™ THC test
.
J Anal Toxicol
1995
;
19
:
5
-
12
.
10.
Hwang
S M
,
Huang
S H
,
Huang
B C
,
Chen
C S
.
Evaluation of five commercial amphetamines and opiates immunoassay test kits in Taiwan
.
J Food Drug Analysis
1994
;
2
(
2
):
89
-
96
.
11.
Towt
J
,
Tsai
S-C J
,
Hernandez
M R
,
Klimov
A D
,
Kravec
C V
,
Rouse
S L
,
Subuhi
H S
,
Twarowska
B
,
Salamone
S J
.
ONTRAK TESTCUP: a novel, on-site, multi-analyte screen for the detection of abused drugs
.
J Anal Toxicol
1995
;
19
:
504
-
10
.
12.
Roche Diagnostic Systems, Inc.
Nutley, NJ 07110-1199. Abuscreen ONLINE® Package Inserts
1991
.
13.
Department of Health and Human Services
.
Mandatory Guideline for Federal Workplace Testing Programs
.
Federal Register
1993
;
58
(
14
):
6062
-
72
.
14.
Department of Transportation (Federal Highway Administration)
.
Drug and Alcohol Testing Programs
. 49 CFR Part 350.
Federal Register
1992
;
57
(
241
):
59516
-
86
.
15.
Roche Diagnostic Systems, Inc.
Nutley, NJ 07110-1199. OnTrak TESTCUP™ Package Inserts.
04
1995
.
16.
Salamone
S J
.
Letter to the Editor. Marijuana detection times: does methodology validate the conclusions
.
J Anal Toxicol
1996
;
20
:204.
17.
Roche Diagnostic Systems, Inc.
Nutley, NJ 07110-1199. Abuscreen ONTRAK® Package Inserts.
09
1994
.
18.
Crouch
D J
,
Alburgues
M E
,
Spanbauer
A C
,
Rollins
D E
,
Moody
D E
,
Chasin
A A
.
Analysis of cocaine and it metabolites from biological specimens using solid-phase extraction and chemical ionization mass spectrometry
.
J Anal Toxicol
1995
;
19
:(
6
)
352
-
8
.
19.
Crouch
D J
,
Peat
M A
,
Chinn
D M
,
Finkle
B S
.
Drugs and Driving: A systematic analytical approach
.
J Forensic Sci
1983
;
28
(
4
):
945
-
56
.
20.
Foltz
R L
,
McGinnis
K M
,
Chinn
D M
.
Quantitative measurement of delta-9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography mass spectrometry
.
Biomedical Mass Spec
1983
;
10
(
5
):
316
-
22
.
This content is only available via PDF.
You do not currently have access to this content.